<SEC-DOCUMENT>0001193125-16-431654.txt : 20160119
<SEC-HEADER>0001193125-16-431654.hdr.sgml : 20160118
<ACCEPTANCE-DATETIME>20160119070153
ACCESSION NUMBER:		0001193125-16-431654
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160115
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160119
DATE AS OF CHANGE:		20160119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911663741
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34475
		FILM NUMBER:		161346936

	BUSINESS ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
		BUSINESS PHONE:		206-676-5000

	MAIL ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d120701d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;15, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>OMEROS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Washington</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-34475</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>91-1663741</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>201 Elliott Avenue West </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seattle, Washington 98119 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(206) 676-5000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On&nbsp;January 15, 2016, Omeros Corporation issued a press release. A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated January 15, 2016</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>OMEROS CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregory A. Demopulos, M.D.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Gregory A. Demopulos, M.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer, and Chairman of the Board of Directors</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: January&nbsp;19, 2016 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated January 15, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d120701dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120701g74k86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEATTLE, WA &#151; January&nbsp;15, 2016 &#151; Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and
commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Omidria<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (phenylephrine and ketorolac injection) 1% / 0.3% will be the focus of a series of presentations and panel discussions by thought leaders in cataract surgery at Hawaiian Eye and Retina, an annual
conference of over 1,200 ophthalmologists, retina specialists, nurses, allied health professionals and administrators. The first of these presentations and discussions will occur on Sunday, January&nbsp;17, 2016, at which time certain information
regarding Omidria will be made public. To ensure that developments regarding Omeros&#146; business are publicly disseminated to securities markets in consistent fashion, Omeros is announcing that the information to be presented at the conference
includes a summary of investigator-sponsored studies, which have resulted in abstracts and manuscripts accepted, submitted or in preparation, reporting that the use of Omidria across a wide range of patients, including those with non-complex
cataracts, complex cataracts, intraoperative floppy iris syndrome (IFIS) and/or pseudoexfoliation, has resulted in statistically significant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduction in complications associated with small pupils; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduction in usage of pupil-expanding devices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prevention of miosis during femtosecond laser-assisted surgery; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduction in age-adjusted surgical times; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improvement in best corrected visual acuity (BCVA) on the day after surgery. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above outcomes are not
referenced in the currently approved labeling for Omidria. Omidria is broadly indicated for use in cataract surgery in adult patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above findings
are from investigator-sponsored, case-controlled/cohort, single-center studies, ranging from approximately 50 to over 1,100 patients, and have not yet been published. Omeros&#146; earlier Phase 3 clinical trials evaluating Omidria were not powered
to demonstrate statistical differences in surgical times and BCVA, and results from those Phase 3 trials did not reach statistical significance for those measurements. Complication rates and use of pupil-expanding devices were not assessed in the
Phase 3 trials, and femtosecond laser cases were excluded for purposes of standardization given that not all investigators in the Omidria Phase 3 program used this equipment in cataract surgery. Consistent with publication guidelines, detailed data
from these investigator-sponsored studies will be available in the published abstracts and journal articles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Omidria</B><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Omeros&#146; PharmacoSurgery<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
product Omidria<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> contains the mydriatic (pupil-dilating) agent phenylephrine and the anti-inflammatory agent ketorolac and was developed for use during cataract or other IOL replacement
surgery. The FDA has approved Omidria for use during cataract surgery or IOL replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Risk Information for Omidria</B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Systemic exposure of phenylephrine may cause elevations in blood pressure. In clinical trials, the most common reported ocular adverse reactions at
two to 24 percent are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation; incidence of adverse events was similar between placebo-treated and Omidria-treated patients. Omidria<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> must be added to irrigation solution prior to intraocular use. Omidria is not approved for use in children. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Omeros Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Omeros is a biopharmaceutical
company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived
from its proprietary PharmacoSurgery<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform, the company&#146;s first drug product, Omidria<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (phenylephrine and ketorolac injection)
1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. In the European
Union, the European Commission (EC) has approved Omidria for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has five
clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntington&#146;s disease, schizophrenia, and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with urologic
surgical procedures. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934, which are subject to the &#147;safe harbor&#148; created by those sections for such
statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;goal,&#148; &#147;intend,&#148; &#147;look forward to,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions
and variations thereof. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros&#146; actual results could differ materially from
those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with product commercialization including with respect to Omidria<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and
OMS103, Omeros&#146; ability to partner and commercialize Omidria<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in Europe, Omeros&#146; unproven preclinical and clinical development activities, regulatory oversight, intellectual property
claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in the company&#146;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission
on November&nbsp;9, 2015. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new
information becomes available in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Cook Williams </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cook Williams Communications, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor and Media Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">360.668.3701 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jennifer@cwcomm.org </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g120701g74k86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120701g74k86.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ <P"I P$1  (1 0,1 ?_$ -$  0 " @(# 0$
M       )"@<(!@L#! 4! @$!  ,  P$! 0            8'" 0%"0,! A
M  8! P($ 04(# \!     0(#! 4&!P 1"!()(1,4"A4Q(C,U-C(C8S06=A<W
M05%A4F(D5&1FMS@Y@4*T576UQ=6V=Y<86'@:.A$  @$"!0($ P()!P@)!0
M 0(#$00 (1(%!C$'02(3"%%A,C,4<8&10F(C<[,64H(T%34V-Z%RDK)#D],7
ML='"PR1TE%88P51D=3C_V@ , P$  A$#$0 _ +_&F&&F&&F&&F&&F&&F&&F&
M&F&-+>8W,RG<1&6+%["V2E'F0\@1<([8 J8KB(HK59 UVN)4DAZU?@#1VB"2
M8[%666*7Y -JDN\W>G9NS\.TMN"K+/N.X)&R5.I+52/O-P ,R8PR!%_.9AX
MXO\ [#]A-][XW&\Q[6YA@VO;))5>GEEO&!^Z6M3D/697U,,U12?$8W,;.4'C
M=N[:JD7;.D4G+9=(P&36073*JBJF8/ Q%$S (#^R ZNJ*6.:-9HB&B=0P(Z$
M$5!'R(SQ0DL4D$K03*5F1BK ]00:$'Y@Y''FU_>/GAIAAIAAIAAIAAIAAIAA
MIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAC\$0 !$1   !$1$=@  \1$1'P
M  #0FF9Z8 $F@ZXIC]P;D&MR3Y/72>C'2\A3*DX''./6I *JFI#P+I5L^D&2
M;99TFX&S6([ETF<@B99!1$! .D"AXE^XSN-+W-[J7EY9.TFS6C_=+0#,&.(D
M%UTE@?6E+R*PS*LH-* #WS]L/;"/M-V@V_;+Q%BW^]3[]>L<B)9E#(C%@I7[
MO (XV!%%=9#4U)-D/M[9<3N&&&F'[!*.9#+''./K..LHD<*INB-Y4T1ZF-:M
MI)-=<LD:%:HGB7BFX=,C&N"AU$ AS^FGMVY>N\\*3AVX2L_+..1PVEZ"0VEM
M!,:APS:C$JFWD)Z3024JNEF\H?=!P=]BY\_.MLA2+A7*I;B^V\J"I:/U-,C,
MA ]/U6(N8AXP3Q$T;4J[[:T!C-6&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&
M&F&&F&&F&&F&&F&&F&&F&-!NY+R'-QYXOVY]$KIDNF1A/C6G%\\J:[5W8V+P
MLS.I)@H1P;X# (N5B'3WZ'0H=6P&UGSW-=Q_^7/:N\N+5@-ZW*ME;YT*F9&]
M649U_5Q!RI'20QUR.-+^T[M:.Z/>&QM[U2=@VJE_=9$AE@=?2A)H5'K3%%(/
M6,24S&*\G _CQ;,K6VTWB"I\/;F6#:=.Y ;Q$\J@K#6'(9*W)N\50BBR+<P.
M$ L3-)=RQ55614],<BY$QW ?.+V_]NMXY=O%YR&QLH;N/8[*6["2E3'+=^C(
MUE$2%S!F56>)F*L$9) M2,>HWN1[I;)PO9+/CVY7\]C<<BOX;)I801+!9&>-
M=QE )\I]!V2.955U]16C9^H]KMS\H#X-Y4LK1?["JC4\M?$ZSDZ<F9 C5JW?
M3CTTPPN4ZX='*@4T79 $SA90P"FW=N!W\=A^WML[KMP3NVNY<BN2NT;N7AO9
M9'HH:5M:7$C-0>28 N[4I&TAZFA^'NI[/+W%[,R;/QFU#;WLGIW&WPQ(69DA
M3TGM854$_K(,D51YGCB'S%@EEW+N+]BRU3L+T&9M.0KA<K='T]HXKE7?-J]&
MO'CE!%R\D9>PC"=;&-0.JJJ9JDY'9N< #?IZO12W]SO:S<^76?"N.SW6X[Q>
M7:6ZF&%EB1G95+.\QB)5 2S&-7R1AUI7S$N/:1WAVKA-_P _Y-;V>U[%86+W
M3+/<(T\BJI*JD4'JT=R%51(T8\ZDFE:2 ZT-C,F&F&&F&&F&&F&&F&&F&&F&
M&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&*H_=%S>7D/RD_1E5GSEY7L0D+CBN(-
MSBK&S.3)J89HVAT8_B@T21>"E'&6\>KX:/1]WX^2/NMYTO<CNK_"FU2,^W;1
M2SB"FJ27DDBB=NM%\U(B3U] $9-CVE]G7;L]K>SG\7;S&D>Z;X3?3EA22*PB
MB8VZT^IB5U3A,J>N-7TXE$PJ,1VS^!C*S7NO+'R79W[ZQ/ZDJX(G)RMWGT7"
M\+7W[EN#L6;*N5>+3._.DD86J:"Y@3,J(@?57"6LO:][?TW3D%L?XFNG:5[<
MFCR7,JDQQ.1J*K#!&&F*@Z LE%+FC8[[@"^]W'N3DVCC=THXE9QI ER 3'':
M0E1+,BMIU//<2,(0S#U&>,:@@JM7^WV1Q<[99[>\CHF(=VJP3%C=Q4"S%A"1
MSF:?KR+AE$L146%I'MU7 E23$YND@ &^O*??=UDWW>KK>I8X89;JXDE*1+HC
M0R.7*QK4Z4!-%6IH*"N6/8/8]IBV#9;/8H)9YX+*UB@629M<KK$BHKR/0:G8
M*"S4%3X8E&X.<9&\3C.7Y[S<NUGH; [Y_=H.D0TZM%3SB=QBLE-3D7."G'OV
MZ))B.#H:%453#RU2*JI'36#HUEV%[61V/%YO<#?3I/9;"[7,=M'*4E,ED5FD
M26B.%]1!1*L/*P+(5?+'7N)[NRWO+H/;5M\#VU_R2-+26[EA$D*P[@#%#)%5
MT8F)\Y"JG-61'5T.J6+"7=SXNY:G8NK6(+5B&>EU6;-BM>FC ]6<2;OTR1&(
M6B&?/FK$%'BQDTUGR3-$P%ZC&()@+K7G!/>%VJYC?Q;3N'WK:-PF8*IN50P%
MS3R^M&S!14D!Y4C6@JQ4FF,4]PO8]WBX3MLV\[5]RWS;8%9W%FSBX6-=1+_=
MY41GH@#,L+2L*T :A.)2B'(H0BB9RJ)J%*<AR& Q#D, &*<ABB)3%,4=P$/
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MH,U$"E!P)"';H+=)R"?JU)?>%S#<]S[C+PPW8M-FL;)1IU-262Z578R:$;2
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M'C$S-C+I-5\F7,Z=HR=+MVP-B*S[LISMJ\Q1(]?((P=,8*DBV)4S@4S=L!Q
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M\EKRM2ZQ8K,UI]>+'U^=M,U.6!RT=R(LHR#KK"1D5RM(UBLX75$A4D4D]S&
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MD2KJ I9'.C2:#S4=D(KFHU4-"0>?>V(S_;LL<"K1C&W/9:6#COER5HU/DY$
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MXBK]SC!1,IVRG<H_9D</ZQGS$4I!.3*+%-'OWR\[7G;A,B:A$U3+0TRY0$%
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MO8O?%LY-PV6Y8"$1^N.N7I^60_.JE.G@GCB&#EM"2_(/".7.YO<T%T9KD[W
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MUPJFQ9,;I&-4R).5OO;5^V;*',1(%1&T.U//!P7D7KW=3LMT!'. *E0"2D@
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MJF\E#0\57HB*@(*/:1,)!QK&'AXI@B1LQC(J,:I,H^/9-TP*FW:,VB!$TR%
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5=1]'Z'\KYTQEK76XY^&F&&F&/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
